For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net revenues | - | 0 | - | - |
| Research and development expense | 1,633,476 | 1,039,713 | 1,958,602 | 892,625.5 |
| General and administrative expenses | 2,447,188 | 1,159,936 | 1,517,415 | 1,326,044.5 |
| Total operating expenses | 4,080,664 | 2,199,649 | 3,476,017 | 2,218,670 |
| Loss from operations | -4,080,664 | -2,199,649 | -3,476,017 | -2,218,670 |
| Unrealized loss on crypto assets | 25,305 | - | - | - |
| Dividend and interest income | 168 | 173 | 181 | 7,074 |
| Change in fair value of investment in joint ventures | - | 0 | - | -145.25 |
| Total other income (expenses), net | -25,137 | 173 | 181 | 6,783 |
| Net loss | -4,105,801 | -2,199,476 | -3,475,836 | -2,211,886.5 |
| Foreign currency translation adjustment | -1,016 | 3,478 | -497 | -11,160.5 |
| Total comprehensive loss | -4,106,817 | -2,195,998 | -3,476,333 | -2,223,047 |
| Net loss per common share, basic (in dollars per share) | -0.3 | -0.17 | -0.27 | -0.365 |
| Net loss per common share, diluted (in dollars per share) | -0.3 | -0.17 | -0.27 | -0.365 |
| Weighted average number of common shares outstanding, basic (in shares) | 13,787,159 | 13,180,243 | 12,727,581 | -3,702,487 |
| Weighted average number of common shares outstanding, diluted (in shares) | 13,787,159 | 13,180,243 | 12,727,581 | -3,702,487 |
Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc. (HOTH)